سعر جونال-اف 900 وحدة دولية قلم 2024

Follitropin alfa (recombinant FSH) 900 IU pre-filled pen (GONAL-f, Serono), 1 pen per pack.

• Anovulation (including polycystic ovarian syndrome) in adult women unresponsive to clomiphene citrate.Population: Adult womenEuropean Medicines Agency (EMA)
• Stimulation of multifollicular development in women undergoing superovulation for assisted reproductive technologies (ART) such as IVF.Population: Adult womenEuropean Medicines Agency (EMA)
• With an LH preparation, stimulation of follicular development in women with severe LH and FSH deficiency.Population: Adult womenEuropean Medicines Agency (EMA)

• EU: most commonly headache, ovarian cysts and local injection-site reactions; mild or moderate OHSS commonly, severe OHSS uncommon; thromboembolism and hypersensitivity reactions very rarely.International label, same formulation · European Medicines Agency (EMA)

• EU: hypersensitivity; tumours of the hypothalamus or pituitary gland; ovarian enlargement or cyst of unknown origin unrelated to polycystic ovarian disease; gynaecological haemorrhage of unknown origin; ovarian, uterine or mammary carcinoma; not to be used when an effective response cannot be obtained (primary ovarian failure, malformations of sexual organs or uterine fibroids incompatible with pregnancy, primary testicular insufficiency).International label, same formulation · European Medicines Agency (EMA)
• US: hypersensitivity to recombinant FSH preparations; high FSH levels indicating primary gonadal failure; uncontrolled non-gonadal endocrinopathies; sex hormone dependent tumours of the reproductive tract; pituitary or hypothalamic tumours; abnormal uterine bleeding or ovarian cyst/enlargement of undetermined origin.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• EU: risk of ovarian hyperstimulation syndrome (OHSS); monitor ovarian response by ultrasound and/or oestradiol; if excessive response, stop treatment and withhold hCG.International label, same formulation · European Medicines Agency (EMA)
• EU: increased incidence of multiple pregnancy (mostly twins) and of ectopic pregnancy in women with tubal disease; thromboembolic events may occur in women with risk factors.International label, same formulation · European Medicines Agency (EMA)

• EU: there is no indication for use during pregnancy; limited data (fewer than 300 pregnancy outcomes) show no malformative or feto/neonatal toxicity, but a teratogenic effect cannot be excluded.International label, same formulation · European Medicines Agency (EMA)
• US: not indicated in pregnant women; verify a negative pregnancy test before administration.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• EU: not indicated during breast-feeding.International label, same formulation · European Medicines Agency (EMA)

English text not available for this section.